Trials / Not Yet Recruiting
Not Yet RecruitingNCT05810142
Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This research project is a single-center, retrospective clinical exploration study. It aims to retrospectively analyze data from 20 patients with advanced duodenal adenocarcinoma who received third-line treatment with furquinelone combined with sintilimab, in order to determine the clinical efficacy and safety of this combination therapy in advanced duodenal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | furquimatinib and sintilimab | furquimatinib and sintilimab |
Timeline
- Start date
- 2023-07-01
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2023-04-12
- Last updated
- 2023-04-12
Source: ClinicalTrials.gov record NCT05810142. Inclusion in this directory is not an endorsement.